- Home
- SSSS vs MGNX Comparison
SSSS vs MGNX Comparison
Compare SSSS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSSS | MGNX |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.4M | 220.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SSSS | MGNX |
|---|---|---|
| Price | $13.27 | $3.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $15.67 | $5.00 |
| AVG Volume (30 Days) | 410.2K | ★ 728.7K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42.86 | $3.19 |
| P/E Ratio | $3.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.50 | $1.19 |
| 52 Week High | $13.66 | $3.88 |
Technical Indicators
Market Signals| Indicator | SSSS | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.45 | 44.94 |
| Support Level | $8.63 | $1.48 |
| Resistance Level | N/A | $3.26 |
| Average True Range (ATR) | 0.53 | 0.21 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 80.00 | 6.01 |
Price Performance
Historical ComparisonAbout SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.